HNF1A-MODY: The Responsive One
Reviewed by CDE Mehandi Sharma · Updated
HNF1A-MODY, also called MODY3, is the subtype most likely to be relevant to an Indian reader. In an Asian Indian clinic study of confirmed MODY, it accounted for 61.7% of cases — by far the largest group.
The HNF1A gene affects how the beta cell develops and functions. Unlike GCK-MODY, the effect is progressive: beta-cell function declines over time, so glucose control tends to worsen with the years rather than staying stable.
The typical picture is a young, lean person with mildly raised fasting glucose but a large rise after meals. That post-meal pattern is characteristic, and it means a fasting test alone can understate the problem.
Some people with HNF1A-MODY also pass glucose in their urine at lower blood glucose levels than usual, because the same gene affects the kidney's glucose handling.
The clinically important feature is treatment. HNF1A-MODY responds markedly well to sulfonylureas — a long-established, inexpensive class of tablet — and typically at low doses. The mechanism is that sulfonylureas stimulate insulin release through a route that bypasses the affected pathway.
That combination is why identifying this subtype matters so much: an effective treatment exists, it is cheap and available in India, and people are frequently on insulin instead because nobody tested them.